Morphotek
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Morphotek sits in the top decile of US sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count).
Morphotek: 20 sponsored US clinical trials, none currently recruiting.
Morphotek sponsors 20 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 13 completed. 1 of these trials are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Adenocarcinoma of the Lung, with 1 trials.
Top-decile sponsor footprint
Morphotek ranks in the top decile of sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
13 of 20 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (65.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
20 total, page 1 of 1
Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)
NCT02357147
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
NCT01748721
Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC
NCT01761240
Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects
NCT01357759
Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation
NCT01574716
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
NCT01507545
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
NCT01521325
A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
NCT01218516
A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma
NCT01212276
Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma
NCT01123304
An Open Label Extension Study of the Efficacy of MORAb-003
NCT01018563
Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer
NCT01004380
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
NCT00849667
A Study of of MORAb-004 in Subjects With Solid Tumors
NCT00847054
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
NCT00738582
An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
NCT00738699
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
NCT00570713
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
NCT00318370
A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer
NCT00325494
Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer
NCT00428766
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 9 |
| Phase 3 | 1 |
How the Morphotek early-phase archive is shaped
20 indexed studies, none listed as recruiting (0% open); 13 completed (65%).
Phase mix: 1 late (III/IV) vs 19 early (I/II) (early-phase heavy).
Top condition: Adenocarcinoma of the Lung (1 trial), 7 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Morphotek: archived-pipeline peers nationwide
Peers matched on 20 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Morphotek sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 20 archived trials
- 59th Medical Wing · 20 trials · 15% recruiting
- Abiomed · 20 trials · 10% recruiting
- Agency for Healthcare Research and Quality (AHRQ) · 20 trials · 0% recruiting
- Alliance Foundation Trials · 20 trials · 15% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Morphotek page
20 registered trials is a research-attention snapshot, not an endorsement of Morphotek or any single study.
- None of Morphotek's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Adenocarcinoma of the Lung is the condition Morphotek studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Adenocarcinoma of the Lung trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Morphotek pipeline card: 20 registered trials from official public datasets.Report a data error.